ADMA Biologics (ADMA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.17
- Estimate
- $0.16
- Surprise
- +3.5%
- Revenue (period 2026-06-30)
- $124.4M
- Score today
- 6.8/10
Revenue source: xbrl.
How the report landed
ADMA Biologics (ADMA) beat the $0.16 estimate with diluted EPS of $0.17 — a clear 3.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ADMA Hold at 6.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +3.5% surprise compares with a -0.3% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Leverage penalty (D/E 1.1): -0.5
- Below 200-MA, MA slope -6.3%/30d (confirmed downtrend)
- Momentum score 4.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.57
- Entry target
- $9.36
- Price target
- $14.79
- Stop
- $8.94
- Upside to target
- +54.5%
- Reward-to-risk
- 9.3:1
The stock trades at 13.7× trailing but 9.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ADMA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.15B
- P/E (fwd)
- 9.8
- P/E (ttm)
- 13.7
- 52-week range
- $7.21–$20.46
- Off 52-week high
- 53.2%
- RSI (14)
- 55
- Volume vs avg
- 0.39×
- Score today
- 6.8/10